Menu
Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Drug discovery – wet AMD and cancer
School of Medicine
Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
@ExonateUK on Twitter
It’s the first day of #ClinicalTrials Awareness week! Together with patients, caregivers, clinical trials sites and more, we conduct clinical trials against the clock, against disease, and against all odds. Check out the video below to learn more. #CTAW2022
Did you know that May is Healthy Vision Month? Find out how we are working with our partners to elevate eye health as a priority on the global health agenda: https://bit.ly/3l4EEl1
We’re building on our legacy of innovation in #prostatecancer and look forward to connecting with researchers and clinicians at the @AmerUrological #AUA22. Learn more about our vision for the future of prostate cancer treatments: https://bit.ly/38dO5fb
#HealthyVisionMonth is here, come and explore our collection of videos, brochures, and interactive applications developed for eye care specialists. Visit our website to learn more about DME, DED, and other disease states.
#Ophthalmology
This #BladderCancerAwarenessMonth, we’re reflecting on the unmet needs of people affected by #bladdercancer. Learn more about the scientific advances we are pursuing to improve outcomes for people living with bladder cancer: https://bit.ly/3Lwa6DW
Chaque année, 3 100 Canadiennes reçoivent un diagnostic de #cancerdelovaire. Nous voulons améliorer le pronostic de toutes les femmes touchées par cette maladie dévastatrice et sauver plus de vies. #AucuneFemmeOubliée
Exonate’s CEO Dr Catherine is delighted to participate in the panel discussion“How will the latest clinical trial design strategies impact innovation”, on the 26th April at 3.20pm at Biotrinity 2022
#corporate #partners #investors #lifesciences #VentureCapital
Nara Daubeney, COO/Co-Founder of @phaimpharma talking about alternatives for autoimmune diseases such as type 1 diabetes at #BioTrinity. What is the relevance for #RareDiseases? AIM therapy can potentially reset the balance for many autoimmune diseases.
